Bal Pharma

BALPHARMA03 May 2024

Pharmaceuticals

₹

-3.06 (-2.96%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Bal Pharma

Bal Pharma

Pharmaceuticals

BALPHARMA03 May 2024

₹

-3.06 (-2.96%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date	Ratio
29-May-2023	D	The Board of Directors of the Company has met today and inter alia transacted the following business. Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company..	18-Sep-2023
30-May-2022	D	The Board of Directors of the Company has met today and inter alia transacted the following business. Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company.	13-Sep-2022
29-Jun-2021	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 29, 2021, inter alia, has recommended dividend of Re. 1/- per equity share of Rs. 10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company.	16-Sep-2021
31-May-2019	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2019, inter alia, has recommended dividend of Re. 1/- per equity share of Rs. 10/- each i.e. 10% for the financial year ended March 31, 2019, which will be paid subject to the approval of members at the ensuing Annual General Meeting of the Company.	17-Sep-2019
30-May-2018	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2018, inter alia, recommended dividend of Re.1/- per equity share of Rs. 10/- each i.e. 10% for the financial year ended March 31, 2018, which will be paid subject to the approval of members at the ensuing Annual General Meeting of the Company.	14-Sep-2018
30-May-2017	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2017, inter alia, has transacted the following :- Recommend a dividend of Re. 1/- per equity share of Rs. 10/- each, thereby appropriating profits to the extent of Rs. 1,41,72,372/- towards dividend, for the financial year ended March 31, 2017. Recommend a dividend of Re.1/- per equity share of Rs.10/- each , thereby appropriating profits to the extent of Rs.1,41,72,372/- towards dividend, for the financial year ended 31.03.2017.	14-Sep-2017
26-May-2016	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2016, inter alia, has recommended a dividend of Re. 1/- per equity share of Rs. 10/- each i.e. 10% on the paid up equity share capital of the Company, for the financial year ended March 31, 2016.	15-Sep-2016
29-May-2015	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2015, inter alia, has recommended a dividend of Rs. 1 per equity share of Rs.10 each i.e. 10% on the paid up equity share capital of the Company, for the financial year ended March 31, 2015.	15-Sep-2015
28-May-2014	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2014, inter alia, has recommended payment of dividend of Re. 1/- (10%) per Equity Share of Rs. 10 each.	12-Sep-2014
28-May-2013	D	Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2013, inter alia, has recommended payment of dividend of Re. 0.75 (7.5%) per equity share of Rs. 10 each.	12-Sep-2013
29-Jun-2009	D	Bal Pharma Limited has informed the Exchange that the Board of Directors, at its meeting held on June 29, 2009 has recommended Dividend of Rs.0.75 per equity share of Rs.10 each. Bal Pharma Limited has informed the Exchange that the Register of members & share transfer books of the Company will remain closed from September 22, 2009 to September 25, 2009 (both days inclusive) for the purpose of payment of Dividend for the financial year, 2008-09. The said payment of dividend is subject to the approval of shareholders of the Company at the ensuing Annual General Meeting (AGM) of the Company to be held on September 25, 2009. (As per NSE Bulletin Dated on 29.07.2009)	17-Sep-2009
24-Jun-2008	D	Bal Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on June 23, 2008 has recommended Dividend of 10% per share as against 7.5% in the previous year.	09-Sep-2008
03-Jul-2007	D	Bal Pharma Limited has informed the Exchange that the Board of Directors at their meeting held on June 30, 2007 has recommended a Dividend of Rs.7.5% per share.	07-Sep-2007
05-Aug-2005	D	7.50% Dividend	09-Sep-2005
31-Mar-2005	R	Members of the Exchange are hereby informed that, Bal Pharma Ltd. has fixed the Record Date for Rights Issue. The transactions in the equity shares of the company should be done on an ex-rights basis with effect from the undermentioned date. THREE Equity Shares of Rs.10/- each at a premium of Rs.20/- per share on rights basis for every FIVE existing equity shares held. Note :- The scrip will be in No Delivery from 07/04/2005 (DR-007/2005-2006) to12/04/2005 (DR-010/2005-2006).	15-Apr-2005	3:5
30-Apr-2024	BC	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve 1.Audited Standalone and Consolidated financi	28-May-2024
25-Jan-2024	BC	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve 1) Un-Audited Standalone and Consolidated finan	12-Feb-2024
20-Nov-2023	BC	Honorable Bangalore bench of National Company Law Tribunal has convened meetings of shareholders and creditors of Transferer Company i.e Golden Drugs Pvt Ltd and Transferee company i.e Bal Pharma Lim	21-Dec-2023
22-Nov-2023	BC	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Thursd	23-Nov-2023
20-Oct-2023	BC	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve 1. Unaudited financial results for the quarter	08-Nov-2023

Announcement Date29-May-2023

Ex Dividend Date18-Sep-2023

Dividend(%)10

Announcement Date30-May-2022

Ex Dividend Date13-Sep-2022

Dividend(%)10

Announcement Date29-Jun-2021

Ex Dividend Date16-Sep-2021

Dividend(%)10

Announcement Date31-May-2019

Ex Dividend Date17-Sep-2019

Dividend(%)10

Announcement Date30-May-2018

Ex Dividend Date14-Sep-2018

Dividend(%)10

Announcement Date30-May-2017

Ex Dividend Date14-Sep-2017

Dividend(%)10

Announcement Date26-May-2016

Ex Dividend Date15-Sep-2016

Dividend(%)10

Announcement Date29-May-2015

Ex Dividend Date15-Sep-2015

Dividend(%)10

Announcement Date28-May-2014

Ex Dividend Date12-Sep-2014

Dividend(%)10

Announcement Date28-May-2013

Ex Dividend Date12-Sep-2013

Dividend(%)8

Announcement Date29-Jun-2009

Ex Dividend Date17-Sep-2009

Dividend(%)8

Announcement Date24-Jun-2008

Ex Dividend Date09-Sep-2008

Dividend(%)10

Announcement Date03-Jul-2007

Ex Dividend Date07-Sep-2007

Dividend(%)8

Announcement Date05-Aug-2005

Ex Dividend Date09-Sep-2005

Dividend(%)8

Record Date01 Jan'1900

Ex-Rights Date01 Jan'1900

Premium(Rs.)20

Ratio3:5

Book Closure

Record Date	Split Date	Purpose
28-May-2024	-	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve 1.Audited Standalone and Consolidated financi
12-Feb-2024	-	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve 1) Un-Audited Standalone and Consolidated finan
21-Dec-2023	-	Honorable Bangalore bench of National Company Law Tribunal has convened meetings of shareholders and creditors of Transferer Company i.e Golden Drugs Pvt Ltd and Transferee company i.e Bal Pharma Lim
23-Nov-2023	-	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Thursd
08-Nov-2023	-	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve 1. Unaudited financial results for the quarter

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Bal Pharma Ltd ₹100.30(-3.06/-2.96%)	100.30	-3.06	158.52	24.95	25.65	1.63
Astrazeneca Pharma India Ltd ₹5,424.45(+90.60/1.70%)	5,424.45	+90.60	13,561.13	71.45	85.02	20.71
Bliss GVS Pharma Ltd ₹119.10(-10.10/-7.82%)	119.10	-10.10	1,246.87	56.07	18.27	1.28
Cipla Ltd ₹1,424.75(+5.20/0.37%)	1,424.75	+5.20	115,033.60	54.70	34.98	4.44
Amrutanjan Health Care Ltd ₹775.50(-11.10/-1.41%)	775.50	-11.10	2,242.02	27.78	50.95	8.56
Abbott India Ltd ₹26,144.45(-459.90/-1.73%)	26,144.45	-459.90	55,556.96	15.92	48.50	17.87

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	81.49	92.30	70.17	81.97	76.56	75.05
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	81.49	92.30	70.17	81.97	76.56	75.05
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.26	0.41	0.45	0.44	0.77	0.38
Total Income	81.75	92.71	70.61	82.41	77.34	75.44
Total Expenditure	73.87	84.65	63.32	73.70	70.26	69.04
PBIDT	7.89	8.07	7.29	8.71	7.08	6.40
Interest	3.66	3.82	3.64	3.84	3.12	2.83
PBDT	4.22	4.25	3.65	4.87	3.96	3.56
Depreciation	2.55	2.02	2.12	1.66	2.03	1.96
Tax	0.66	0.99	0.54	-0.72	0.77	1.08
Deferred Tax	-0.24	-0.36	-0.20	1.80	-0.31	-0.61
Reported Profit After Tax	1.26	1.60	1.20	2.12	1.47	1.13
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	1.26	1.60	1.20	2.12	1.47	1.13

EPS (Unit Curr.)	0.80	1.02	0.76	1.35	0.94	0.72
EPS (Adj) (Unit Curr.)	0.80	1.02	0.76	1.35	0.94	0.72
Calculated EPS (Unit Curr.)	0.80	1.02	0.76	1.35	0.94	0.72
Calculated EPS (Adj) (Unit Curr.)	0.80	1.02	0.76	1.35	0.94	0.72
Calculated EPS (Ann.) (Unit Curr.)	3.18	4.08	3.05	5.41	3.75	2.90
Calculated EPS (Adj) (Ann.) (Unit Curr.)	3.18	4.08	3.05	5.41	3.75	2.90
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	15.80	15.69	15.69	15.69	15.69	15.57
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	9.68	8.74	10.39	10.63	9.25	8.53
PBDTM(%)	5.18	4.60	5.20	5.94	5.17	4.74
PATM(%)	1.55	1.73	1.71	2.59	1.92	1.51

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	81.66	92.54	70.39	82.45	76.62	75.31
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	81.66	92.54	70.39	82.45	76.62	75.31
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.10	0.14	0.16	0.19	0.46	0.05
Total Income	81.76	92.68	70.54	82.64	77.08	75.36
Total Expenditure	73.87	84.85	63.94	74.29	70.47	69.53
PBIDT	7.89	7.84	6.60	8.35	6.61	5.82
Interest	3.66	3.82	3.64	3.85	3.11	2.86
PBDT	4.23	4.02	2.96	4.50	3.50	2.97
Depreciation	2.96	2.42	2.53	2.09	2.45	2.37
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.66	0.99	0.54	-0.72	0.77	1.08
Deferred Tax	-0.24	-0.36	-0.20	1.51	-0.31	-0.61
Reported Profit After Tax	0.85	0.97	0.09	1.62	0.59	0.13
Minority Interest After NP	-0.04	0.02	0.01	0.02	0.02	0.01
Net Profit after Minority Interest	0.89	0.95	0.08	1.60	0.57	0.11

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.89	0.95	0.08	1.60	0.57	0.11

EPS (Unit Curr.)	0.54	0.62	0.06	1.03	0.38	0.08
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	15.80	15.69	15.69	15.69	15.69	15.57

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	9.66	8.47	9.38	10.13	8.63	7.73
PBDTM(%)	5.18	4.34	4.21	5.46	4.57	3.94
PATM(%)	1.04	1.05	0.13	1.96	0.77	0.17

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	15.69	14.82	14.82	14.17	14.17	14.17
Reserves Total	80.34	71.56	63.56	51.77	62.69	58.06
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.94	0.94	0.00	0.00	0.00
Total Shareholders Funds	96.03	87.32	79.32	65.94	76.86	72.23
Secured Loans	125.23	98.01	104.04	98.63	96.33	82.51
Unsecured Loans	0.00	0.00	0.21	0.80	8.15	8.00
Total Debt	125.23	98.01	104.25	99.43	104.48	90.51
Total Liabilities	221.26	185.33	183.57	165.37	181.34	162.74
APPLICATION OF FUNDS :
Gross Block	107.22	92.12	86.13	82.36	76.19	71.43
Less : Accumulated Depreciation	44.15	39.22	33.48	26.23	19.25	13.15
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	63.07	52.90	52.65	56.13	56.94	58.28
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	1.16	0.00	0.11	0.06	0.21
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	8.40	8.40	8.40	7.42	7.44	7.44
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	97.69	73.97	60.12	67.55	69.52	66.17
Sundry Debtors	94.84	77.91	69.44	51.66	65.69	64.06
Cash and Bank	7.35	5.09	3.72	2.95	4.08	4.03
Loans and Advances	70.07	61.23	59.92	46.55	49.21	47.23
Total Current Assets	269.95	218.20	193.20	168.71	188.50	181.48
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	110.82	89.97	65.59	63.17	66.38	75.13
Provisions	6.63	5.14	0.97	0.49	0.96	2.37
Total Current Liabilities	117.45	95.12	66.56	63.66	67.33	77.50
Net Current Assets	152.50	123.08	126.64	105.05	121.17	103.99
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	2.72	2.72	0.00	0.00	0.00	0.96
Deferred Tax Liability	5.58	5.18	4.40	4.05	4.18	8.52
Net Deferred Tax	-2.86	-2.46	-4.40	-4.05	-4.18	-7.56
Total Assets	221.11	183.08	183.29	164.66	181.43	162.37
Contingent Liabilities	16.44	16.25	13.86	12.99	20.29	7.75

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	15.69	14.82	14.82	14.17	14.17	14.17
Reserves Total	48.10	42.87	37.82	38.25	52.47	50.82
Equity Share Warrants	0.00	0.94	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.94	0.00	0.00	0.00
Total Shareholders Funds	63.79	58.63	53.58	52.42	66.64	64.99
Minority Interest	-0.09	-0.13	-0.23	-7.10	-6.42	-4.79
Secured Loans	124.68	97.71	104.04	98.63	115.35	101.53
Unsecured Loans	6.32	5.93	5.98	19.82	8.15	8.00
Total Debt	131.00	103.64	110.02	118.45	123.50	109.53
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	6.74	8.78	7.63	6.83	4.91	3.33
Total Liabilities	201.44	170.92	171.00	170.60	188.63	173.06
APPLICATION OF FUNDS :
Gross Block	127.10	111.45	105.10	97.70	89.76	84.71
Less: Accumulated Depreciation	50.64	44.06	36.52	27.00	19.37	13.23
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	76.46	67.39	68.58	70.70	70.39	71.48
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	1.61	0.00	3.32	3.63	0.21
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.02	0.02
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	98.01	74.40	60.39	67.71	69.75	66.49
Sundry Debtors	93.98	75.31	67.20	49.60	64.70	64.05
Cash and Bank	7.61	5.39	3.85	3.13	4.32	4.15
Loans and Advances	28.56	29.47	32.72	36.92	44.28	50.07
Total Current Assets	228.15	184.57	164.15	157.37	183.05	184.77
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	102.22	83.90	65.47	63.68	67.53	77.17
Provisions	6.64	5.12	0.98	0.50	0.96	2.37
Total Current Liabilities	108.86	89.02	66.45	64.18	68.49	79.54
Net Current Assets	119.30	95.55	97.70	93.19	114.55	105.22
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	2.17	0.09	0.95	3.90	1.64	0.96
Deferred Tax Liability	2.87	0.69	3.58	7.49	5.82	8.53
Net Deferred Tax	-0.70	-0.60	-2.63	-3.59	-4.18	-7.57
Other Assets	6.39	6.96	7.35	6.99	4.23	3.70
Total Assets
Contingent Liabilities	16.44	16.25	12.99	12.99	20.29	7.75

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.81	0.89	0.68	2.20	2.58
Net Cash from Operating Activities	5.07	30.57	10.23	21.71	11.55
Net Cash Used In Investing Activities	-22.08	-13.43	-6.66	-3.30	-11.98
Net Cash Used In Financing Activities	17.43	-17.22	-3.36	-19.94	0.05
Net Inc./Dec In Cash And Cash Equivalents	0.42	-0.08	0.21	-1.52	-0.38
Cash And Cash Equivalents At End Of The Year	1.23	0.81	0.89	0.68	2.20

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

51.23%

FII Shareholding

0.13%

DII Shareholding

0.00%

Public Shareholding

48.64%

**Promoter pledged shareholding 51.23%

About Bal Pharma Ltd

Bal Pharma Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 158.52 crores. It has reported a sales of Rs. 81.49 crores and a net profit of Rs. 1.26 crores for the quarter ended December 2018. The company management includes , Shailesh Siroya,C V Srinivas,Himesh Virupakshaya,H S Venkatesh,Nicola Neeladri,Jatish Sheth,Kotian Chittananda Damodar,Abdul Basith (Bal Pharma Ltd) among others.

Chairman

Registered office

21 & 22 Bommasandra Indl Area,Hosur Road,Bangalore,Karnataka,560092

FAX :

Background

Incorporation Year1987

Face Value₹10

Market Lot1

How to buy Bal Pharma shares on nse?

To buy Bal Pharma shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Bal Pharma share price today?

The Bal Pharma shares price on nse is Rs.100.3 today.

What is the market cap of Bal Pharma shares on BSE ?

The company has a market capitalization of Rs.158.52Cr

What is the PE & PB ratio of Bal Pharma shares ?

PE is 25.65 and PB is 1.63

What is the 52 Week High and Low of Bal Pharma shares?

Bal Pharma stock price high: Rs.132.2 Bal Pharma stock price low: Rs.80